Differences in serum biochemistry between breast-fed and formula-fed infants
Tzee-Chung Wu1, I-Fei Huang, Yi-Chun Chen
1Division of Gastroenterology and Nutrition, Children's Medical Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|November 22, 2011
Summary
Breast milk and formula feeding lead to distinct infant serum biochemistry profiles, with breast-fed infants showing higher levels of cholesterol, liver enzymes, and bilirubin. These findings provide crucial reference values for infant health monitoring.
Area of Science:
- Pediatric Biochemistry
- Infant Nutrition
- Clinical Chemistry
Background:
- Investigating differences in serum biochemistry between breast-fed and formula-fed infants.
- Establishing reference values for serum biochemistry in infants at 4 and 8 weeks old for clinical use.
Purpose of the Study:
- To compare serum biochemistry levels in breast-fed versus formula-fed infants.
- To provide normative data for serum biochemistry at different infant ages.
Main Methods:
- Study included 60 healthy infants (30 breast-fed, 30 formula-fed).
- Anthropometric measurements (weight, length, head circumference) were recorded at 4 and 8 weeks old.
- 14 serum biochemistry markers were analyzed.
Main Results:
- No significant differences in growth parameters between groups.
- Breast-fed infants had higher serum cholesterol, triglycerides, ALT, AST, GGT, and bilirubin levels.
- Breast-fed infants had lower serum BUN and inorganic phosphate levels compared to formula-fed infants.
- Significant age-related changes in serum biochemistry were observed in both groups.
Conclusions:
- Infant nutrition source significantly impacts serum biochemistry.
- Serum biochemistry reference values vary with postnatal age.
- These findings aid in interpreting infant laboratory results.
More Related Videos
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:30Development of Human Microbiota
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...